GSA Capital Partners LLP Has $626,000 Stock Position in Personalis, Inc. (NASDAQ:PSNL)

GSA Capital Partners LLP grew its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 6.2% during the 1st quarter, Holdings Channel reports. The firm owned 420,141 shares of the company’s stock after buying an additional 24,498 shares during the period. GSA Capital Partners LLP’s holdings in Personalis were worth $626,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PSNL. State of Michigan Retirement System increased its holdings in shares of Personalis by 11.3% during the 1st quarter. State of Michigan Retirement System now owns 493,798 shares of the company’s stock worth $736,000 after acquiring an additional 50,000 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of Personalis during the 4th quarter worth approximately $152,000. Bruce & Co. Inc. increased its holdings in shares of Personalis by 100.0% during the 4th quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock worth $630,000 after acquiring an additional 150,000 shares during the last quarter. Finally, ARK Investment Management LLC increased its holdings in shares of Personalis by 16.6% during the 4th quarter. ARK Investment Management LLC now owns 6,671,545 shares of the company’s stock worth $14,010,000 after acquiring an additional 952,118 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Trading Down 2.4 %

NASDAQ:PSNL opened at $1.66 on Friday. The stock has a fifty day moving average price of $1.38 and a 200-day moving average price of $1.47. Personalis, Inc. has a fifty-two week low of $0.89 and a fifty-two week high of $2.43.

Personalis (NASDAQ:PSNL) last released its earnings results on Wednesday, May 8th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.18. The firm had revenue of $19.53 million during the quarter, compared to the consensus estimate of $18.49 million. Personalis had a negative return on equity of 58.31% and a negative net margin of 124.89%. Analysts expect that Personalis, Inc. will post -1.26 earnings per share for the current year.

Analyst Ratings Changes

PSNL has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $3.50 target price on shares of Personalis in a report on Friday, June 21st. Lake Street Capital initiated coverage on Personalis in a report on Tuesday, April 30th. They set a “buy” rating and a $4.00 target price on the stock.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.